A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT06806033 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Non-Hodgkins Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Gemcitabine
DRUG: Oxaliplatin

Sponsor

Hoffmann-La Roche